Zydus Cadila cracks one more USFDA approval to cure High Blood Pressure

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to exchanges in India on Friday, Cadila Healthcare Ltd said of getting one more approval from US FDA (Food & Drug Administration) to market tablets to cure high blood pressure and prevent heart failure.

Zydus Cadila has received the final approval from the USFDA to market Spironolactone Tablets USP (US RLD – Aldactone Tablets) in strengths of 25 mg, 50 mg and 100 mg.

It is  used to treat high blood pressure and heart failure.

Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

It is also used to treat swelling (edema) caused by certain conditions like heart failure and liver disease by removing excess fluid and improving symptoms such as breathing problems.

The drug will be manufactured at the group’s manufacturing facility at Baddi.


In line with this, the group now has 210 approvals and has so far filed over 330 ANDAs (Abbreviated New Drug Application) since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally.

Zydus aspires to be a research-based pharmaceutical company by 2020.

Announcement was well reciprocated by investors and traders as the Cadila Healthcare shares opened in RED Zone on negative counters but traded throughout the day in GREEN Zone and ended on positive counters.